Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Approves Once-Daily Mesalamine for Ulcerative Colitis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

FDA Approves Once-Daily Mesalamine for Ulcerative Colitis

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Shire received approval from the FDA for Lialda (mesalamine) with MMX technology, indicated for patients with active mild-to-moderate ulcerative colitis. Lialda is the only FDA-approved once-daily oral formulation of mesalamine. Shire will launch the drug in the U.S. in 1Q2007.

Other currently available mesalamines require three to four doses daily of 6 to 16 pills. A recent study conducted by the Crohn’s and Colitis Foundation of America (CCFA) found that 65% of patients with ulcerative colitis are poorly compliant with their medication, citing pill burden and inconvenience associated with the medication.

The FDA approval was based on the results of two Phase III studies that found Lialda (2.4 g/day and 4.8 g/day) was effective in inducing remission in patients with active, mild to moderate ulcerative colitis compared to placebo after eight weeks of treatment. Lialda is generally well tolerated and has a similar safety profile to other currently available mesalamines.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters